|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date11 Apr 2005 |
A Phase 1, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects
The purpose of this study is to assess the safety and tolerability of ocular administration of Topical Interleukin-1-Receptor Antagonist in healthy volunteers. Additionally, the PK of Interleukin-1-Receptor Antagonist will be assessed.
100 Clinical Results associated with China Chengdu Rhodiola Biological Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with China Chengdu Rhodiola Biological Pharmaceutical Co., Ltd.
100 Deals associated with China Chengdu Rhodiola Biological Pharmaceutical Co., Ltd.
100 Translational Medicine associated with China Chengdu Rhodiola Biological Pharmaceutical Co., Ltd.